When Your Health Is Your Business

By Katie Walsh • December 23, 2018 12:23pm ESTIt’s been a month since a federal judge in Georgia blocked the rollout of a pill that has been billed as a “gold standard” in the fight against obesity.

The generic version of the pill was scheduled to be available on the market this week.

But the ruling by U.S. District Judge Matthew Stover on Thursday means that the generic version will have to be blocked by a federal appeals court, which has ordered a stay on the final approval of the drug.

The drug, called Lipitor, has been a long time coming.

Its approval has been delayed by multiple appeals courts in multiple countries.

But when it was finally approved in March, the FDA made sure to include some limitations, such as a high rate of side effects, a lower risk of severe side effects and limited potential for serious side effects.

In June, the U.K. Court of Appeal ruled that Lipitor’s manufacturer should be required to submit additional data to the FDA before approval, including how many people in the U, UK and Australia had taken the drug at the same time and in the same place.

That data was not submitted to the U: it was kept secret.

So it is up to Stover to decide whether to allow the FDA to block Lipitor in the United States.

He said in a ruling that he would have to make a decision by December 30.

The ruling means that Lipiter won’t be available to the public for another year, and if you or anyone you know has been taking the pill, you will need to talk to a doctor.

The FDA also says that it is unable to provide data about the effectiveness of Lipitor as a weight loss drug, because the manufacturer has not yet submitted data that will enable the agency to make such a determination.

What do you think?

Should the FDA block Lipiter?

Let us know in the comments.